Efficacy and Safety of Dordaviprone (ONC201) in Prospective Clinical Trials of Adult and Pediatric Recurrent H3 K27M-Mutant Diffuse Glioma Patients
Dordaviprone shows 16.7% response rate in adults with recurrent H3 K27M gliomas, with durable responses lasting median 15.1 months.